Mitochondrially Targeted Gene Therapy Rescues Visual Loss in a Mouse Model of Leber’s Hereditary Optic Neuropathy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242317068 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Tsung-Han Chou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Optic Atrophy, Hereditary, Leber, Mitochondrial Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIH HHS, National Eye Institute.
Abstract (Originalsprache)
Leber’s hereditary optic neuropathy (LHON) is a common mitochondrial genetic disease, causing irreversible blindness in young individuals. Current treatments are inadequate, and there is no definitive cure. This study evaluates the effectiveness of delivering wildtype human NADH ubiquinone oxidoreductase subunit 4 (hND4) gene using mito-targeted AAV(MTSAAV) to rescue LHOH mice. We observed a declining pattern in electroretinograms amplitudes as mice aged across all groups (p < 0.001), with significant differences among groups (p = 0.023; Control vs. LHON, p = 0.008; Control vs. Rescue, p = 0.228). Inner retinal thickness and intraocular pressure did not change significantly with age or groups. Compared to LHON mice, those rescued with wildtype hND4 exhibited improved retinal visual acuity (0.29 ± 0.1 cy/deg vs. 0.15 ± 0.1 cy/deg) and increased functional hyperemia response (effect of flicker, p < 0.001, effect of Group, p = 0.004; Interaction Flicker × Group, p < 0.001). Postmortem analysis shows a marked reduction in retinal ganglion cell density in the LHON group compared to the other groups (Effect of Group, p < 0.001, Control vs. LHON, p < 0.001, Control vs. Rescue, p = 0.106). These results suggest that MTSAAV-delivered wildtype hND4 gene rescues, at least in part, visual impairment in an LHON mouse model and has the therapeutic potential to treat this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
ORCID-Profile: Tsung-Han Chou, Diego Alba, Vittorio Porciatti, Hong Yu
Förderung
- NEI NIH HHS
- NIH HHS
- National Eye Institute
Zitieren
APA
Chou, T. H., Hao, Z., Alba, D., Lazo, A., Gallo Afflitto, G., Eastwood, J. D., Porciatti, V., Guy, J., & Yu, H. (2023). Mitochondrially Targeted Gene Therapy Rescues Visual Loss in a Mouse Model of Leber’s Hereditary Optic Neuropathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242317068
Vancouver
Chou TH, Hao Z, Alba D, Lazo A, Gallo Afflitto G, Eastwood JD, et al. Mitochondrially Targeted Gene Therapy Rescues Visual Loss in a Mouse Model of Leber’s Hereditary Optic Neuropathy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242317068
BibTeX
@article{Chou2023,
author = {Chou, Tsung-Han and Hao, Zixuan and Alba, Diego and Lazo, Angelina and Gallo Afflitto, Gabriele and Eastwood, Jeremy D and Porciatti, Vittorio and Guy, John and Yu, Hong},
title = {Mitochondrially Targeted Gene Therapy Rescues Visual Loss in a Mouse Model of Leber’s Hereditary Optic Neuropathy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242317068}
}
EUVIMED